Recent News

• 06.01.2026 - Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
• 05.08.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.27.2026 - Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
• 03.19.2026 - MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
• 03.06.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.03.2026 - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
• 02.24.2026 - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.01.2026 - 3 Initial statement of beneficial ownership of securities
• 05.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.27.2026 - 8-K Current report
• 04.27.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.27.2026 - EX-99.1 EX-99.1